Similarly, we tested an immunocompetent, syngeneic model of KRASG12C mutant lung cancer using 3LL ΔNRAS cells, a variant of Lewis lung carcinoma that harbors an endogenous KRASG12C mutation and responds to KRAS inhibitors (39). This evidence concerns the gene KRAS and lung carcinoma.